Pipe Distribution As a Harm Reduction Service for People Who Use Methamphetamine

Overview

Journal Subst Use Misuse

Publisher Informa Healthcare

Date 2024 Dec 20

PMID 39702015

Authors

Alex Rains

Erin Augustine

Kyle Miller

John Bresett

Rebecca Bolinski

Trevor Thompson

Babatunde Patrick Ajayi

Will Nicholson

Scott Fletcher

Wiley D Jenkins

Mai T Pho

Lawrence J Ouellet

Jerel M Ezell

Affiliations

Soon will be listed here.

Abstract

Background: Methamphetamine use is disproportionately high in rural settings, with rates increasing during the COVID-19 pandemic. While syringe service programs reduce disease transmission among people who inject drugs, limited research exists around the value of smoking equipment, specifically pipes, in minimizing harms associated with rural methamphetamine use.

Methods: We conducted semi-structured interviews with people who use methamphetamine in rural southern Illinois. Inclusion criteria involved methamphetamine use in the past 30 days. Interview guides explored attitudes and behaviors regarding pipe use practices and pipe access. Interviews were recorded, transcribed, and coded. The data were analyzed for emergent themes using a sequential, deductive process.

Results: Nineteen participants, average age 37.1 (SD + 8.7), were interviewed. 53% were women, and 89% were white. All reported smoking methamphetamine, and 84% reported injecting. Participants reported engaging in smoking instead of injection to decrease wounds, pain, and infections. Smoking enabled some to use socially as opposed to alone, as was typically the case when they injected. Participants expressed interest in pipe distribution through a harm reduction agency. They shared that, were a harm reduction agency to distribute pipes, it would connect people to other services such as HIV testing, naloxone, and safer sex supplies.

Conclusions: Pipe distribution may function as a harm reduction strategy by decreasing injection and solitary drug use and linking patients to additional services. Given disproportionate methamphetamine use in rural regions, this intervention could specifically address drug-related harms that impact rural populations.

References

Pro G, Hayes C, Montgomery B, Zaller N . Demographic and geographic shifts in the preferred route of methamphetamine administration among treatment cases in the US, 2010-2019. Drug Alcohol Depend. 2022; 237:109535. DOI: 10.1016/j.drugalcdep.2022.109535. View

Simpson K, Kral A, Goldshear J, Wenger L, Strike C, Bluthenthal R . Reasons for assisting with injection initiation: Results from a large survey of people who inject drugs in Los Angeles and San Francisco, California. Drug Alcohol Depend. 2020; 209:107885. PMC: 7127951. DOI: 10.1016/j.drugalcdep.2020.107885. View

Schranz A, Barocas J . Infective Endocarditis in Persons Who Use Drugs: Epidemiology, Current Management, and Emerging Treatments. Infect Dis Clin North Am. 2020; 34(3):479-493. PMC: 7945002. DOI: 10.1016/j.idc.2020.06.004. View

Enns A, Pinto A, Venugopal J, Grywacheski V, Gheorghe M, Kakkar T . Substance use and related harms in the context of COVID-19: a conceptual model. Health Promot Chronic Dis Prev Can. 2020; 40(11-12):342-349. PMC: 7745829. DOI: 10.24095/hpcdp.40.11/12.03. View

Bolinski R, Walters S, Salisbury-Afshar E, Ouellet L, Jenkins W, Almirol E . The Impact of the COVID-19 Pandemic on Drug Use Behaviors, Fentanyl Exposure, and Harm Reduction Service Support among People Who Use Drugs in Rural Settings. Int J Environ Res Public Health. 2022; 19(4). PMC: 8872091. DOI: 10.3390/ijerph19042230. View

Novak S, Kral A . Comparing injection and non-injection routes of administration for heroin, methamphetamine, and cocaine users in the United States. J Addict Dis. 2011; 30(3):248-57. PMC: 3225003. DOI: 10.1080/10550887.2011.581989. View

Ashford R, Curtis B, Brown A . Peer-delivered harm reduction and recovery support services: initial evaluation from a hybrid recovery community drop-in center and syringe exchange program. Harm Reduct J. 2018; 15(1):52. PMC: 6198436. DOI: 10.1186/s12954-018-0258-2. View

Tong A, Sainsbury P, Craig J . Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007; 19(6):349-57. DOI: 10.1093/intqhc/mzm042. View

McLuckie C, Pho M, Ellis K, Navon L, Walblay K, Jenkins W . Identifying Areas with Disproportionate Local Health Department Services Relative to Opioid Overdose, HIV and Hepatitis C Diagnosis Rates: A Study of Rural Illinois. Int J Environ Res Public Health. 2019; 16(6). PMC: 6466434. DOI: 10.3390/ijerph16060989. View

10.

Pauly B . Harm reduction through a social justice lens. Int J Drug Policy. 2008; 19(1):4-10. DOI: 10.1016/j.drugpo.2007.11.005. View

11.

Uuskula A, Raag M, Barnes D, Tross S, Ave T, Des Jarlais D . Adapted "Break the Cycle for Avant Garde" intervention to reduce injection assisting and promoting behaviours in people who inject drugs in Tallinn, Estonia: A pre- post trial. PLoS One. 2023; 18(5):e0266815. PMC: 10231841. DOI: 10.1371/journal.pone.0266815. View

12.

Hunter C, Strike C, Barnaby L, Busch A, Marshall C, Shepherd S . Reducing widespread pipe sharing and risky sex among crystal methamphetamine smokers in Toronto: do safer smoking kits have a potential role to play?. Harm Reduct J. 2012; 9:9. PMC: 3306827. DOI: 10.1186/1477-7517-9-9. View

13.

Schalkoff C, Lancaster K, Gaynes B, Wang V, Pence B, Miller W . The opioid and related drug epidemics in rural Appalachia: A systematic review of populations affected, risk factors, and infectious diseases. Subst Abus. 2019; 41(1):35-69. PMC: 7012683. DOI: 10.1080/08897077.2019.1635555. View

14.

Meyers S, Smith L, Werb D . Preventing transitions into injection drug use: A call for gender-responsive upstream prevention. Int J Drug Policy. 2020; 83:102836. PMC: 7793169. DOI: 10.1016/j.drugpo.2020.102836. View

15.

Jones C, Underwood N, Compton W . Increases in methamphetamine use among heroin treatment admissions in the United States, 2008-17. Addiction. 2019; 115(2):347-353. PMC: 6982538. DOI: 10.1111/add.14812. View

16.

Dew B, Elifson K, Dozier M . Social and environmental factors and their influence on drug use vulnerability and resiliency in rural populations. J Rural Health. 2008; 23 Suppl:16-21. DOI: 10.1111/j.1748-0361.2007.00119.x. View

17.

Davis S, Kristjansson A, Davidov D, Zullig K, Baus A, Fisher M . Barriers to using new needles encountered by rural Appalachian people who inject drugs: implications for needle exchange. Harm Reduct J. 2019; 16(1):23. PMC: 6444507. DOI: 10.1186/s12954-019-0295-5. View

18.

Glick S, Prohaska S, LaKosky P, Juarez A, Corcorran M, Des Jarlais D . The Impact of COVID-19 on Syringe Services Programs in the United States. AIDS Behav. 2020; 24(9):2466-2468. PMC: 7182093. DOI: 10.1007/s10461-020-02886-2. View

19.

Strike C, Watson T, Lavigne P, Hopkins S, Shore R, Young D . Guidelines for better harm reduction: evaluating implementation of best practice recommendations for needle and syringe programs (NSPs). Int J Drug Policy. 2010; 22(1):34-40. DOI: 10.1016/j.drugpo.2010.03.007. View

20.

Drucker E, Anderson K, Haemmig R, Heimer R, Small D, Walley A . Treating Addictions: Harm Reduction in Clinical Care and Prevention. J Bioeth Inq. 2016; 13(2):239-49. DOI: 10.1007/s11673-016-9720-6. View